Have you read this week's news from Citius Pharmaceuticals, Inc. (CTXR)? If not, do so now

StockWireNews

Keep Eyes On This Low Float NASDAQ Profile With Recent Major News - Displays Wild Upside Potential

DJS $7.00 Price Target / Analyst Report

April 3rd

Good Morning,

Have you read this week's news from Citius Pharmaceuticals, Inc. (CTXR)?

With the global pandemic not looking like it will come to an end anytime soon, it will be important to watch companies trying to provide/create services that could help combat this virus.

That's why after yesterday's pullback, CTXR could be potentially undervalued with tons of upside potential.

Additionally, it could see some serious support from its 13-Day Exponential Moving Average (approximately $.61 after hours Thursday).

Read the news below now:

Citius Signs Exclusive Option with Novellus to License Novel Stem-Cell Therapy for Acute Respiratory Distress Syndrome (ARDS) Associated with CV-19

- Novellus's patented mRNA-based cell-reprogramming technology creates unique mesenchymal stem cells (MSCs) with superior immunomodulatory properties and manufacturing advantages over primary adult donor-derived MSCs - much greater supply and faster scale-up

- MSCs prevent and suppress cytokine storm believed to be the cause of the severe inflammation of ARDS and now seen in CV-19 patients

CRANFORD, N.J., April 1, 2020 /PRNewswire/ -- Citius Pharmaceuticals, Inc. ("Citius" or the "Company") (Nasdaq: CTXR), a specialty pharmaceutical company focused on developing and commercializing critical care drug products, today signed an exclusive six-month option agreement to in-license a stem-cell therapy for acute respiratory distress syndrome (ARDS) from a subsidiary of Novellus, Inc., a preclinical-stage biotechnology company based in Cambridge, MA.

Novellus's patented process uses its exclusive non-immunogenic synthetic messenger ribonucleic acid (mRNA) molecules to create induced pluripotent stem cells (iPSCs) that, in turn, generate mesenchymal stem cells (MSCs) with superior immunomodulatory properties. MSCs have been shown to be safe in over 900 clinical trials and to be safe and effective in treating a number of inflammatory diseases, including ARDS.

Read The Full Article Here.

-----

A $7.00 Price Target Gives CTXR Serious Potential Upside

A rough calculation from CTXR's Thursday's close (approximately $.7399 per share), gives this stock profile a ton of upside potential.

If CTXR is able to find enough momentum to push through its 52-week high of $1.50 in the short-term, this stock could really start making moves.

Link Dawson James Securities Analyst Report.

-----

image

I'll be in touch later again today. Talk soon.

Sincerely,

Kai Parker

StockWireNews


(Always Remember The Stock Prices Could Be Significantly Lower Now From The Dates I Provided.)

Disclosure: I am not a lice.nsed finan.cial adviser. All potential percentage gains are based on from the low to the high of day. StockWireNews full disclosure is to be read and fully understood before using StockWireNews website, or joining StockWireNews' email or text list. By viewing StockWireNews website and/or reading Stock Wire News email or text newsletter you are agreeing to StockWireNews full disclosure which can be read at www.stockwirenews.net/disclosure Make sure to always do your own research and due diligence on any day and swing profile I bring to your attention. Stock Wire News (stock wire news . com) is owned by Stock News Wire LLC, a limited liability company. A member of Stock News Wire, LLC owns an interest in the limited liability company that owns and operates small cap firm . com ("SCF") and an interest in the limited liability company that owns and operates fierce analyst . com ("FI"). From time to time, non-affiliated third parties hire Stock Wire News, SCF and/or FI jointly to publicly disseminate information about a company via website, email, SMS and other points of media. Pursuant to an agreement between StockWireNews LLC and Venado Media LLC (a non affiliated 3rd party), StockWireNews was hired for a period beginning on 7/26/19 and ending on 7/29/19 to publicly disseminate information about (CTXR) via Website, Email and SMS. We were paid twenty thousand USD via bank wire transfer. We own zero shares of (CTXR). Pursuant to an agreement between StockWireNews LLC and Venado Media LLC (a non affiliated 3rd party), StockWireNews has been hired for a period beginning on 9/3/19 and ending on 9/4/19 to publicly disseminate information about (CTXR) via Website, Email and SMS. We were paid twenty thousand USD via bank wire transfer. We own zero shares of (CTXR). Pursuant to an agreement between StockWireNews LLC and Venado Media LLC (a non affiliated 3rd party), StockWireNews has been hired for a period beginning on 12/18/19 and ending on 12/19/19 to publicly disseminate information about (CTXR) via Website, Email and SMS. We were paid twenty thousand USD via bank wire transfer. We own zero shares of (CTXR). Pursuant to an agreement between StockWireNews LLC and Venado Media LLC (a non affiliated 3rd party), StockWireNews has been hired for a one day period on 2/4/20 to publicly disseminate information about (CTXR) via Website, Email and SMS. We were paid twenty thousand USD via bank wire transfer. We own zero shares of (CTXR). Pursuant to an agreement between StockWireNews LLC and Venado Media LLC (a non affiliated 3rd party), StockWireNews has been hired for a one day period on 3/11/20 to publicly disseminate information about (CTXR) via Website, Email and SMS. We were paid seven thousand five hundred USD via bank wire transfer. We own zero shares of (CTXR). Pursuant to an agreement between StockWireNews LLC and Venado Media LLC (a non affiliated 3rd party), StockWireNews has been hired for a period beginning on 4/2/20 and ending on 4/3/20 to publicly disseminate information about (CTXR) via Website, Email and SMS. We were paid twenty-five thousand five hundred USD via bank wire transfer. We own zero shares of (CTXR). In total, we have now been compensated one hundred and twenty thousand USD via bank wire transfer to disseminate information about (CTXR).